Leap Therapeutics (LPTX) News Today $0.30 +0.01 (+1.82%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Leap Therapeutics Reports Q2 2025 Financial ResultsAugust 15, 2025 | msn.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deLeap Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | prnewswire.comLeap Therapeutics, Inc. (LPTX) - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comLeap Therapeutics Initiates Process To Explore Strategic OptionsJune 24, 2025 | nasdaq.comLeap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic AlternativesJune 23, 2025 | prnewswire.comLeap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finanznachrichten.deLeap Therapeutics Reports First Quarter 2025 Financial ResultsMay 13, 2025 | prnewswire.comLeap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual MeetingApril 25, 2025 | prnewswire.comLeap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal CancerApril 15, 2025 | prnewswire.comLeap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study TranscriptMarch 31, 2025 | seekingalpha.comH.C. Wainwright Reaffirms Their Hold Rating on Leap Therapeutics (LPTX)March 27, 2025 | markets.businessinsider.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyMarch 26, 2025 | finanznachrichten.deLeap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | finanznachrichten.deLeap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 26, 2025 | prnewswire.comLeap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyMarch 26, 2025 | prnewswire.comWhat is HC Wainwright's Estimate for LPTX FY2029 Earnings?January 30, 2025 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Downgraded to Hold Rating by Baird R WJanuary 30, 2025 | marketbeat.comLeap Therapeutics downgraded to Neutral from Buy at H.C. WainwrightJanuary 29, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Leap Therapeutics (LPTX)January 29, 2025 | msn.comLeap Therapeutics stock rating cut by H.C. Wainwright to NeutralJanuary 29, 2025 | msn.comLeap Therapeutics (NASDAQ:LPTX) Downgraded by HC Wainwright to NeutralJanuary 29, 2025 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Stock Rating Lowered by Robert W. BairdJanuary 29, 2025 | marketbeat.comLeap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug ResultsJanuary 28, 2025 | marketwatch.comLeap Therapeutics stock hits 52-week low at $0.8January 28, 2025 | msn.comLeap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancerJanuary 28, 2025 | msn.comLeap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish StudyJanuary 28, 2025 | prnewswire.comPositive Buy Rating for Leap Therapeutics Driven by Promising Clinical Results and Robust Pipeline AdvancementsJanuary 17, 2025 | markets.businessinsider.comLeap Therapeutics (NASDAQ:LPTX) Receives "Buy" Rating from HC WainwrightJanuary 16, 2025 | marketbeat.comLeap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon CancerJanuary 6, 2025 | seekingalpha.comLeap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | prnewswire.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Up 50.7% in DecemberDecember 28, 2024 | marketbeat.comLeap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | prnewswire.comBuy Recommendation for Leap Therapeutics: Promising Phase 2 Trial Developments and Stable Financial OutlookNovember 15, 2024 | markets.businessinsider.comLeap Therapeutics Reports Q3 2024 Progress and FinancialsNovember 15, 2024 | markets.businessinsider.comSimplify Asset Management Inc. Grows Position in Leap Therapeutics, Inc. (NASDAQ:LPTX)November 15, 2024 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Receives Buy Rating from HC WainwrightNovember 15, 2024 | marketbeat.comLeap Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | prnewswire.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Sees Significant Drop in Short InterestOctober 27, 2024 | marketbeat.comLeap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer PatientsSeptember 30, 2024 | prnewswire.comLeap Therapeutics (NASDAQ:LPTX) Stock Crosses Below Fifty Day Moving Average of $2.58September 28, 2024 | marketbeat.comSimplify Asset Management Inc. Buys 255,293 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)September 20, 2024 | marketbeat.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest UpdateAugust 31, 2024 | marketbeat.comLeap Therapeutics Inc (5MC.MU)August 23, 2024 | sg.finance.yahoo.com3 Trending Biotech Penny StocksAugust 22, 2024 | 247wallst.comVanguard Group Inc. Acquires 457,904 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)August 20, 2024 | marketbeat.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short InterestAugust 19, 2024 | marketbeat.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 15, 2024 | finanznachrichten.deQ3 2024 EPS Estimates for Leap Therapeutics, Inc. (NASDAQ:LPTX) Decreased by AnalystAugust 15, 2024 | marketbeat.comMaintained Buy Rating for Leap Therapeutics Amid Promising Clinical and Financial OutlookAugust 14, 2024 | markets.businessinsider.com Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LPTX Media Mentions By Week LPTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LPTX News Sentiment▼1.870.99▲Average Medical News Sentiment LPTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LPTX Articles This Week▼10▲LPTX Articles Average Week Get the Latest News and Ratings for LPTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Leap Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Precision BioSciences News Lantern Pharma News Barinthus Biotherapeutics News Jasper Therapeutics News Telomir Pharmaceuticals News Century Therapeutics News Annovis Bio News Shattuck Labs News Klotho Neurosciences News FibroGen News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LPTX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access